Comparative Pharmacology
Head-to-head clinical analysis: E E S versus ERYTHRA DERM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: E E S versus ERYTHRA DERM.
E.E.S. vs ERYTHRA-DERM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin (E.E.S.) binds to the 50S subunit of bacterial ribosomes, inhibiting peptide chain elongation and protein synthesis. It also exhibits prokinetic effects on the gastrointestinal tract via motilin receptor agonism.
Erythromycin, a macrolide antibiotic, binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis. It also exhibits anti-inflammatory and immunomodulatory effects, reducing neutrophil chemotaxis and bacterial lipase production.
250-500 mg every 6 hours orally or 15-20 mg/kg/day IV divided every 6 hours.
Apply a thin layer to the affected area(s) twice daily. For topical use only. Adult dose is 2% solution or ointment.
None Documented
None Documented
1.5-2 hours in adults with normal renal function; prolonged to 4-6 hours in patients with hepatic impairment; may be shorter in children.
Terminal elimination half-life of 2-4 hours; prolonged to 5-6 hours in hepatic impairment.
Primarily hepatic (biliary) excretion of unchanged drug and active metabolites; approximately 15% of an oral dose is excreted unchanged in urine. The remainder is eliminated via feces as unchanged drug and metabolites.
Primarily biliary fecal elimination (60-70%); renal excretion of unchanged drug <15%.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic